Jason L. Weirather
Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer
Most-Cited Works
- → MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma(2018)572 cited
- → Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis(2017)507 cited
- → Full‐length transcriptome sequences and splice variants obtained by a combination of sequencing platforms applied to different root tissues of Salvia miltiorrhiza and tanshinone biosynthesis(2015)364 cited
- → Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma(2020)333 cited
- → Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade(2021)270 cited
- → Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial(2022)228 cited
- → Serial Quantitative PCR Assay for Detection, Species Discrimination, and Quantification of Leishmania spp. in Human Samples(2011)188 cited
- → A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma(2020)136 cited
- → The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative(2019)135 cited
- → Interferon Regulatory Factor 6 Promotes Differentiation of the Periderm by Activating Expression of Grainyhead-Like 3(2012)131 cited